Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Amasten on its offer for SSM
Mandate

Vinge advises Amasten on its offer for SSM

October 16, 2020 Capital Markets and Public M&A EU, Competition and Regulatory Banking and Finance Real Estate and Construction Corporate Tax

Vinge advises Amasten Fastighets AB (publ) in connection with its public offer to the shareholders of SSM Holding AB (publ) (“SSM”)

The offer consideration consists of shares in Amasten, corresponding to a value of approximately SEK 400 million. Amasten is a property company that manages, develops and builds. The property portfolio consists of 92 percent housing, whereby the remaining area consists of office, retail, industrial and community premises. SSM produces smart, affordable homes with attractive shared spaces close to public transport and the city centre for its target group – tomorrow’s urbanites.

Vinge’s team consists of Jesper Schönbeck, Rikard Lindahl, Malte St Cyr Ohm, Boris Kotur, Clara Sohlberg, Lisa Malmborg and Emil Lindwall (Capital Markets and Public M&A), Johan Wahlbom and Joel Kokko (EU, Competition and Regulatory), Pauline Lagerstrand and Felix Möller (Banking and Finance), Henrik Wastenson (Corporate Tax) as well as Kristofer Larson (Real Estate).


Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026